Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

ABSTRACT: Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

PROVIDER: PRJNA885078 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21739346.fastq.gz	Fastqsanger.gz
	SRR21739347.fastq.gz	Fastqsanger.gz
	SRR21739348.fastq.gz	Fastqsanger.gz
	SRR21739349.fastq.gz	Fastqsanger.gz
	SRR21739350.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 45

Similar Datasets

Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

Project description:We describe the transcriptomic changes in neuroepithelial organoids in response to all-trans retinoic acid.

2022-10-01 | GSE214368 | GEO

Addition of retinoic acid to kidney organoids

Project description:Addition of retinoic acid to kidney organoids

| PRJNA694466 | ENA

Addition of retinoic acid to kidney organoids

Project description:The addition of 5uM retinoic acid to kidney organoids at day 12 (day 7+5). This data is from the same experimental batch as data within GSE119561.

2022-03-02 | GSE165408 | GEO

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA721930 | ENA

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA1061109 | ENA

Effect of Exogenous Retinoic Acid on human iPSCs derived intestinal organoids

Project description:Retinoic acid promotes the in vitro growth, patterning and improves the cellular composition of human pluripotent stem-cell-derived intestinal organoids

2022-09-02 | GSE212333 | GEO

All-trans retinoic acid effect on the squamous cell carcinoma cell line ME180: time course

Project description:All-trans retinoic acid (ATRA) has been shown to have anti-proliferative effects, particularly in the context of cancer. However, the effects of ATRA on gene and microRNA expression in solid tumors have not been investigated. In this study, we performed gene expression and microRNA analysis of the squamous cell carcinoma cell line, ME180, following treatment with 10 micromolar all-trans retinoic acid (ATRA) for 1, 3, and 6 hours. Results provide insight into the temporal regulation of genes and microRNAs by retinoids.

2014-08-01 | GSE54464 | GEO

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Project description:This SuperSeries is composed of the following subset Series: GSE34672: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [Illumina HumanHT-12 gene expression array] GSE34725: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [ChIP-Seq] Refer to individual Series

2012-03-14 | E-GEOD-34726 | biostudies-arrayexpress

Transcription profiling of F9 teratocarcinoma sublines characterized by the presence or absence of the RAR gamma nuclear retinoic acid receptor treated with trans retinoic acid and the novel retinoid, ST1926

Project description:Effect of all trans retinoic acid and the novel retinoid, ST1926, on the profile of gene expression in F9 teratocarcinoma sublines characterized by the presence or absence of the RAR gamma nuclear retinoic acid receptor

2005-12-31 | E-MEXP-361 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data